drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous BCMA-directed CAR T-cell therapy (genetically modified CD3+ T cells expressing a chimeric antigen receptor targeting BCMA) for relapsed/refractory multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ciltacabtagene Autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD3+ T cells are genetically modified to express a chimeric antigen receptor targeting BCMA on myeloma plasma cells. CAR binding to BCMA triggers T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity, leading to selective killing and clearance of BCMA-expressing malignant cells.
drug_name
Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528)
nct_id_drug_ref
NCT05666700